Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company (HZNP) Stock Competitors & Peer Comparison
See (HZNP) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HZNP | $116.30 | +0.00% | 26.6B | 61.86 | $1.88 | N/A |
| LLY | $812.69 | +0.90% | 770.4B | 65.98 | $12.32 | +0.69% |
| JNJ | $168.30 | -0.74% | 405B | 18.02 | $9.34 | +2.98% |
| ABBV | $190.28 | -0.29% | 336.2B | 81.35 | $2.34 | +3.39% |
| NVO | $71.70 | +1.37% | 317.7B | 19.44 | $3.69 | +2.25% |
| NVS | $117.70 | +0.20% | 229B | 17.15 | $6.86 | +3.40% |
| AZN | $72.66 | -1.38% | 225.3B | 29.29 | $2.48 | +2.12% |
| MRK | $84.71 | +0.71% | 212.8B | 12.32 | $6.88 | +3.76% |
| AMGN | $306.58 | -0.64% | 164.8B | 27.92 | $10.98 | +3.02% |
| GILD | $116.20 | +2.65% | 144.5B | 15.01 | $7.74 | +2.68% |
Stock Comparison
HZNP vs LLY Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, LLY has a market cap of 770.4B. Regarding current trading prices, HZNP is priced at $116.30, while LLY trades at $812.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas LLY's P/E ratio is 65.98. In terms of profitability, HZNP's ROE is +0.11%, compared to LLY's ROE of +0.77%. Regarding short-term risk, HZNP is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check LLY's competition here
HZNP vs JNJ Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, JNJ has a market cap of 405B. Regarding current trading prices, HZNP is priced at $116.30, while JNJ trades at $168.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas JNJ's P/E ratio is 18.02. In terms of profitability, HZNP's ROE is +0.11%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, HZNP is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check JNJ's competition here
HZNP vs ABBV Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, ABBV has a market cap of 336.2B. Regarding current trading prices, HZNP is priced at $116.30, while ABBV trades at $190.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas ABBV's P/E ratio is 81.35. In terms of profitability, HZNP's ROE is +0.11%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, HZNP is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check ABBV's competition here
HZNP vs NVO Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, NVO has a market cap of 317.7B. Regarding current trading prices, HZNP is priced at $116.30, while NVO trades at $71.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas NVO's P/E ratio is 19.44. In terms of profitability, HZNP's ROE is +0.11%, compared to NVO's ROE of +0.81%. Regarding short-term risk, HZNP is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check NVO's competition here
HZNP vs NVS Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, NVS has a market cap of 229B. Regarding current trading prices, HZNP is priced at $116.30, while NVS trades at $117.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas NVS's P/E ratio is 17.15. In terms of profitability, HZNP's ROE is +0.11%, compared to NVS's ROE of +0.23%. Regarding short-term risk, HZNP is less volatile compared to NVS. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check NVS's competition here
HZNP vs AZN Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, AZN has a market cap of 225.3B. Regarding current trading prices, HZNP is priced at $116.30, while AZN trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas AZN's P/E ratio is 29.29. In terms of profitability, HZNP's ROE is +0.11%, compared to AZN's ROE of +0.19%. Regarding short-term risk, HZNP is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check AZN's competition here
HZNP vs MRK Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, MRK has a market cap of 212.8B. Regarding current trading prices, HZNP is priced at $116.30, while MRK trades at $84.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas MRK's P/E ratio is 12.32. In terms of profitability, HZNP's ROE is +0.11%, compared to MRK's ROE of +0.38%. Regarding short-term risk, HZNP is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check MRK's competition here
HZNP vs AMGN Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, AMGN has a market cap of 164.8B. Regarding current trading prices, HZNP is priced at $116.30, while AMGN trades at $306.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas AMGN's P/E ratio is 27.92. In terms of profitability, HZNP's ROE is +0.11%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, HZNP is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check AMGN's competition here
HZNP vs GILD Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GILD has a market cap of 144.5B. Regarding current trading prices, HZNP is priced at $116.30, while GILD trades at $116.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GILD's P/E ratio is 15.01. In terms of profitability, HZNP's ROE is +0.11%, compared to GILD's ROE of +0.32%. Regarding short-term risk, HZNP is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GILD's competition here
HZNP vs PFE Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, PFE has a market cap of 141.1B. Regarding current trading prices, HZNP is priced at $116.30, while PFE trades at $24.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas PFE's P/E ratio is 17.98. In terms of profitability, HZNP's ROE is +0.11%, compared to PFE's ROE of +0.09%. Regarding short-term risk, HZNP is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check PFE's competition here
HZNP vs SNY Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SNY has a market cap of 122.7B. Regarding current trading prices, HZNP is priced at $116.30, while SNY trades at $50.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SNY's P/E ratio is 17.25. In terms of profitability, HZNP's ROE is +0.11%, compared to SNY's ROE of +0.08%. Regarding short-term risk, HZNP is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SNY's competition here
HZNP vs CELG-RI Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CELG-RI has a market cap of 100B. Regarding current trading prices, HZNP is priced at $116.30, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, HZNP is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CELG-RI's competition here
HZNP vs BMY Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BMY has a market cap of 98.6B. Regarding current trading prices, HZNP is priced at $116.30, while BMY trades at $48.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BMY's P/E ratio is 18.08. In terms of profitability, HZNP's ROE is +0.11%, compared to BMY's ROE of +0.32%. Regarding short-term risk, HZNP is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check BMY's competition here
HZNP vs GSK Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GSK has a market cap of 76.7B. Regarding current trading prices, HZNP is priced at $116.30, while GSK trades at $37.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GSK's P/E ratio is 18.52. In terms of profitability, HZNP's ROE is +0.11%, compared to GSK's ROE of +0.22%. Regarding short-term risk, HZNP is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GSK's competition here
HZNP vs BIIB Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, BIIB has a market cap of 19.3B. Regarding current trading prices, HZNP is priced at $116.30, while BIIB trades at $131.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas BIIB's P/E ratio is 13.00. In terms of profitability, HZNP's ROE is +0.11%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, HZNP is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check BIIB's competition here
HZNP vs GRFS Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, GRFS has a market cap of 8.7B. Regarding current trading prices, HZNP is priced at $116.30, while GRFS trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas GRFS's P/E ratio is 37.41. In terms of profitability, HZNP's ROE is +0.11%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, HZNP is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check GRFS's competition here
HZNP vs OGN Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, OGN has a market cap of 2.7B. Regarding current trading prices, HZNP is priced at $116.30, while OGN trades at $10.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas OGN's P/E ratio is 3.55. In terms of profitability, HZNP's ROE is +0.11%, compared to OGN's ROE of +1.82%. Regarding short-term risk, HZNP is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check OGN's competition here
HZNP vs CTOR Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CTOR has a market cap of 154.4M. Regarding current trading prices, HZNP is priced at $116.30, while CTOR trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CTOR's P/E ratio is -5.18. In terms of profitability, HZNP's ROE is +0.11%, compared to CTOR's ROE of -0.34%. Regarding short-term risk, HZNP is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CTOR's competition here
HZNP vs SCLX Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SCLX has a market cap of 83.1M. Regarding current trading prices, HZNP is priced at $116.30, while SCLX trades at $11.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SCLX's P/E ratio is -0.78. In terms of profitability, HZNP's ROE is +0.11%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, HZNP is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SCLX's competition here
HZNP vs SCLXW Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SCLXW has a market cap of 78M. Regarding current trading prices, HZNP is priced at $116.30, while SCLXW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SCLXW's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, HZNP is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SCLXW's competition here
HZNP vs MIRA Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, MIRA has a market cap of 30.1M. Regarding current trading prices, HZNP is priced at $116.30, while MIRA trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas MIRA's P/E ratio is -3.68. In terms of profitability, HZNP's ROE is +0.11%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, HZNP is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check MIRA's competition here
HZNP vs SRXH Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, SRXH has a market cap of 7.6M. Regarding current trading prices, HZNP is priced at $116.30, while SRXH trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas SRXH's P/E ratio is N/A. In terms of profitability, HZNP's ROE is +0.11%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, HZNP is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check SRXH's competition here
HZNP vs CRXT Comparison July 2025
HZNP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HZNP stands at 26.6B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, HZNP is priced at $116.30, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HZNP currently has a P/E ratio of 61.86, whereas CRXT's P/E ratio is -0.02. In terms of profitability, HZNP's ROE is +0.11%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, HZNP is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for HZNP.Check CRXT's competition here